scholarly journals Differential expression of methyltransferase METTL1 associates with death in a cohort of patients with triple negative breast cancer.

2019 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed Gene ◽  
Whole Genome ◽  
Disease Course ◽  
The Third ◽  
Genome Profiling ◽  
Whole Genome Profiling

Whole genome profiling data of 226 patients with triple negative breast cancer using a published dataset (1) was stratified based on survival. When comparing the transcriptomes of 87 patients that expired versus 123 patients that survived, the methyltransferase like 1 METTL1 was the third most differentially expressed gene in the entire transcriptome. METTL1 mediates 7-methylguanosine modification of microRNAs and tRNAs (2,3,4,5,6). Increased expression of METTL1 is an indication that the disease course will likely result in fatality in patients with triple negative breast cancer and should be treated accordingly.

scholarly journals Olfactory receptors OR5B21 and OR6C76 are differentially expressed in humans with triple negative breast cancer.

2019 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Olfactory Receptor ◽  
Triple Negative ◽  
Olfactory Receptors ◽  
Differentially Expressed ◽  
Survival Outcomes ◽  
Whole Genome ◽  
Genome Profiling ◽  
Whole Genome Profiling

Whole genome profiling data of 226 patients with triple negative breast cancer (1) was stratified based on survival. When comparing the transcriptomes of 87 patients that expired versus 123 patients that survived, two olfactory receptors were among the genes whose expression was most different. We previously reported that genes of the olfactory receptor superfamily were differentially expressed in metastases in the HER2+ Balb-NeuT mouse model of breast cancer (2). The data here indicate that differential expression of OR5B21 and OR6C76 associates with survival outcomes in humans with triple negative breast cancer.

scholarly journals Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer

Mathematics ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 222
Author(s):  
Juan C. Laria ◽  
M. Carmen Aguilera-Morillo ◽  
Enrique Álvarez ◽  
Rosa E. Lillo ◽  
Sara López-Taruella ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Variable Selection ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
A Priori ◽  
Simulated Data ◽  
Point Of View ◽  
High Dimensional ◽  
Whole Genome ◽  
Genome Context

Over the last decade, regularized regression methods have offered alternatives for performing multi-marker analysis and feature selection in a whole genome context. The process of defining a list of genes that will characterize an expression profile remains unclear. It currently relies upon advanced statistics and can use an agnostic point of view or include some a priori knowledge, but overfitting remains a problem. This paper introduces a methodology to deal with the variable selection and model estimation problems in the high-dimensional set-up, which can be particularly useful in the whole genome context. Results are validated using simulated data and a real dataset from a triple-negative breast cancer study.

scholarly journals Differential expression of cyclin A2 in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Primary Tumors ◽  
Ductal Cells ◽  
Cyclin A2

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding cyclin A2, CCNA2, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CCNA2 was also differentially expressed in bulk tumor in human breast cancer (3). CCNA2 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CCNA2 in primary tumors of the breast was correlated with overall survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of CCNA2 was correlated with overall survival in patients with basal-like 1, basal-like 2, and mesenchymal subtype disease. CCNA2 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression, function and prognostic value of miR-17–92 cluster in ER-positive and triple-negative breast cancer

2020 ◽  
Vol 25 ◽  
pp. 100224 ◽  
Author(s):  
Muhammad Mosaraf Hossain ◽  
Afrin Sultana ◽  
David Barua ◽  
Md Nahidul Islam ◽  
Ananya Gupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Triple Negative Breast Cancer ◽  
Prognostic Value ◽  
Triple Negative ◽  
Er Positive

scholarly journals Differential expression of maternal embryonic leucine zipper kinase in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Leucine Zipper ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Primary Tumors ◽  
Free Survival ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding maternal embryonic leucine zipper kinase, MELK, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). MELK was also differentially expressed in bulk tumor in human breast cancer (3). MELK mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of MELK in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of MELK was correlated with distant metastasis-free survival in patients with basal-like 1 and luminal androgen receptor subtype disease. MELK may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of abnormal spindle microtubule assembly in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Microtubule Assembly ◽  
Spindle Microtubule ◽  
Primary Tumors ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding abnormal spindle microtubule assembly, ASPM, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). ASPM was also differentially expressed in bulk tumor in human breast cancer (3). ASPM mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of ASPM in primary tumors of the breast was correlated with recurrence-free survival in patients with basal-like and luminal A type cancer, while within triple negative breast cancer, primary tumor expression of ASPM was correlated with overall survival in patients with basal-like 1 subtype disease. ASPM may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Sign in / Sign up

Export Citation Format

Share Document